The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

A Clinician View and Experience of Proteomic Studies in the Light of Lung Cancer in Japanese Healthcare

På svenska

Author

  • Harubumi Kato
  • Toshihide Nishimura
  • Takashi Hirano
  • Masaharu Nomura
  • Hiromasa Tojo
  • Kiyonaga Fujii
  • Takeshi Kawamura
  • Sayaka Mikami
  • Makoto Kihara
  • Yasuhiko Bando
  • Masahiro Tsuboi
  • Norihiko Ikeda
  • György Marko-Varga
Show all

Summary, in English

In Japan, rising costs have impacted the framework of maintaining an efficient and effective healthcare system. Today, urgent implementation of programs to address this need have led to a rebuilding of the entire approach of medical evaluation and clinical care. Recent developments in clinical proteomics based on mass spectrometry (MS) for identifying, sequencing, and quantifying disease-relevant protein biomarkers is a promising means for optimal drug prescription using biomarker diagnosis. We illustrate in this report our experience with lung cancer cases with various drug therapies evaluated with proteomics studies.

Publishing year

2011

Language

English

Pages

51-57

Publication/Series

Journal of Proteome Research

Volume

10

Issue

1

Document type

Journal article (comment)

Publisher

The American Chemical Society (ACS)

Topic

  • Analytical Chemistry

Keywords

  • lung cancer
  • diagnosis and treatment
  • proteomic study
  • healthcare

Status

Published

ISBN/ISSN/Other

  • ISSN: 1535-3893